Abstract. One-step nucleic acid amplification (OSNA) targeting cytokeratin 19 (CK19) mRNA expression and pathological examination are widely used for the intraoperative diagnosis of sentinel node (SN) metastasis. The aim of the present study was to develop a novel assay for detecting SN metastasis by targeting Ras association domain-containing protein 1 (RASSF1A) methylation in tumor cells, and to compare its performance with OSNA. Using digital PCR with methylation-specific restriction enzymes (RE-dMSP), our assay was able to detect ≥3 copies of methylated DNA per well, and was ≥10 times more sensitive than real-time PCR with bisulfite modification. OSNA lysates were examined using RE-dMSP and digital PCR for PIK3CA mutation, in the event that primary tumors were PIK3CA mutation-positive. RE-dMSP revealed a high concordance of 95.0% (153/161) with OSNA, and 100% (59/59) with PIK3CA mutation for detecting SN metastasis. In 11 breast cancer cell lines, the variation in methylated RASSF1A copy number was significantly lower than that of CK19 mRNA (2.8 vs. 10.5-fold; P<0.01). RE-dMSP has the potential to more accurately detect SN metastasis, and to more precisely estimate total tumor loads in SN, compared with OSNA.

Introduction

Sentinel lymph node (SN) biopsy is widely used to determine axillary lymph node (LN) status in clinically node-negative breast cancer patients (1,2). In practice, SN metastasis is detected by intraoperative histopathological examination of frozen section(s) or cytological observation of touch imprints, and is confirmed by postoperative pathological examination of permanent sections (3,4). One-step nucleic acid amplification (OSNA) can be used to detect SN metastasis through the amplification of cytokeratin 19 (CK19) mRNA (which is expressed in tumor cells, but not normal cells of LNs) with the same accuracy as routine pathological examination (5). OSNA is also used to determine total tumor load (TTL) in SNs as the sum of CK19 mRNA copies, which is reportedly useful for predicting non-SN metastatic status (6,7), as well as patient prognosis (8).

However, TTL determination by OSNA does not always accurately reflect the total number of tumor cells in the SN, since the copy number of CK19 mRNAs per tumor cell varies considerably. In fact, it is reported that OSNA predicts a 30-fold difference in CK19 mRNA copies among tumors of the same size (9). By contrast, the amount of DNA per tumor cell is thought to be less variable, thus the detection of SN tumor cells from tumor-derived DNA is considered to more accurately determine TTL.

Ras association domain-containing protein 1 (RASSF1A) promoter methylation is one of the most frequently observed epigenomic changes in breast cancer (10,11). Methylation-specific PCR (MSP) following bisulfite treatment is widely used to quantify methylated DNA. However, bisulfite treatment often results in considerable DNA loss (12,13), and requires specialized optimization for digital PCR (dPCR) (14). A novel dPCR technique for the detection of methylated DNA was recently reported, using a methylation-specific restriction enzyme without bisulfite treatment (15-17). The aim of the present study was to develop a highly sensitive dPCR assay to detect RASSF1A methylation following restriction enzyme digestion (RE-dMSP), for the detection of tumor-derived methylated RASSF1A in SN lysates.

Materials and methods

Patients and samples. A total of 87 patients with breast cancer who underwent surgery with sentinel lymph node biopsy (SNB), and whose SNs were examined by OSNA at Osaka University between November 2015 and April 2017, were retrospectively included in this study (Fig. 1). The study was approved by the Ethical Review Board of Osaka University Hospital (approval date/number: 14 Aug 2014/#14111), and informed consent
was obtained from each patient. Of the 87 patients, 10 were excluded due to a lack of OSNA lysates, and six were excluded due to the lack of RASSF1A methylation in their primary tumors. Ultimately, 161 LNs from 71 patients were included, and 166 lysates were analyzed (the LN was separated into two lysates in three SNs, and three lysates in one SN, due to its large size). SNB was performed with a combination of dye (patent blue and/or indocyanine green) and radiocolloid (technetium-99m tin colloid) or dye alone. A 1-mm-thick slice was cut from the center of each SN and intraoperatively subjected to frozen section analysis. The remaining LN tissue was used for OSNA, where the SN was homogenized in 4 ml Lymphorhag solution (Sysmex Corporation), of which 20 µl lystate was used. The remaining lystate was stored at -80°C until use. The CK19 copy number per assay was classified as follows: >5,000, (++); >250 and ≤5,000, (+); >0 and ≤250, (-); and 0, (N.D.). OSNA (++) and (+) were considered to be positive, and isolated tumor cells (ITCs) were considered negative for SN metastasis.

Detection of RASSF1A methylation using RE-dMSP. DNA was extracted from 100 µl SN lysate using the QIAamp Circulating Nucleic Acid Kit (Qiagen GmbH) and eluted in 50 µl desalted water. DNA solution (6.6 µl) was incubated for 16 h at 37°C in a final volume of 20 µl, containing 1X ddPCR Supermix for probes (Bio-Rad Laboratories, Inc.), 900 nM each primer, 250 nM probe and 10 U HhaI, HpaII (New England BioLabs, Inc.) and BstUI (Thermo Fisher Scientific, Inc.) each. These three methylation-sensitive restriction enzymes were selected since they can be used at the same incubation temperature (37°C). The reaction time was set to 16 h (16,17) to allow for the complete digestion of unmethylated DNA. Methylation analysis was performed using three wells per assay. As a control to confirm the presence of DNA, the DNA solution (2.0 µl) was also incubated without restriction enzymes. The primers (18) and probe (Universal ProbeLibrary #19; cat. no. 04686926001; Roche Diagnostics GmbH) are presented in Fig. 2 and Table SI. After incubation, droplet generation oil was added, and the mixture was loaded onto a QX100 droplet generator (Bio-Rad Laboratories, Inc.). Then, 40 µl emulsified mixture was subjected to PCR using a T100 thermal cycler (Bio-Rad Laboratories, Inc.) under the following conditions: 95°C for 10 min, followed by 50 cycles at 95°C for 15 sec and 60°C for 60 sec, with a final cycle at 50°C for 10 sec. KRT19 (CK19) gene expression was analyzed by Platinum® qPCR SYBR® Green Mix (Invitrogen; Thermo Fisher Scientific, Inc.) and quantified using the QX100 Droplet Reader and QuantaSoft software version 1.7.4 (both Bio-Rad Laboratories, Inc.). The presence of ≥2 dots/well was regarded as a positive result, and the copy numbers of three positive wells were totaled. The results for each SN divided into multiple lysates were summed.

For methylation analysis of primary breast tumors, DNA was extracted from three 10-µm formalin-fixed paraffin-embedded (FFPE) tumor sections using the QIAamp DNA FFPE kit (Qiagen GmbH), and RE-dMSP was performed. For sensitivity analysis of RE-dMSP, 0, 1, 3, 10, 30 and 100 copies of methylated DNA template (EpiScope®; Methylated HeLa DNA; Takara Bio, Inc.) spiked in 10,000 copies of unmethylated DNA from the peripheral blood leukocytes of a healthy individual were subjected to RE-dMSP with or without restriction enzymes. Conventional MSP with real-time PCR after bisulfite modification (qMSP) was performed as previously reported (19). The initial amount of DNA before bisulfite treatment was adjusted so that the input DNA copy number per well was the same as that of RE-dMSP. The sensitivity and positive detection rates were compared between the RE-dMSP and qMSP assays over eight wells. Mutation analysis of PIK3CA in SNs and primary tumors. For the mutational analysis of primary breast tumors, DNA extracted from the FFPE tissue sections was subjected to real-time PCR analysis to detect the PIK3CA-H1047R mutation, as previously reported (20). For PIK3CA-mutation detection in SNs, DNA was extracted from 100 µl SN lysate and eluted in 50 µl desalted water. Then, 9 µl DNA solution was subjected to QuantStudio™ 3D dPCR (Thermo Fisher Scientific, Inc.) (20). The sequences of the primers and probes are displayed in Table SI.

Estimation of DNA fragment size of methylated RASSF1A in SN tissues. DNA was extracted from 100 µl SN lysate and eluted with 50 µl desalted water. To estimate the fragment size of the methylated DNA, 14 µl DNA from each SN lysate was electrophoresed on a 2% agarose gel, and subsequently separated into short (<500 bp) and long (>500 bp) fragments. The DNA was extracted from each fraction using the QIAquick Gel Extraction Kit (Qiagen GmbH) and RE-dMSP was performed.

Immunohistochemistry analysis of CK19. The expression of CK19 protein in primary breast tumors was assessed using immunohistochemistry with 4-µm FFPE tissue sections. Immunohistochemical staining of each section was performed as previously described (21) with mouse monoclonal anti-CK19 primary antibody (clone, RCK 108; 1:50; Dako; Agilent Technologies, Inc.) and a peroxidase-conjugated secondary antibody [cat. no. 414131F; Histofine Simple Stain MAX PO (M); Nichirei Biosciences, Inc.] Each of these sections was visualized with 3,3-diaminobenzidine tetrahydrochloride (Wako Pure Chemical Industries, Ltd.) and counterstained with hematoxylin.

Quantification of methylated RASSF1A and CK19 mRNA in breast cancer cell lines. A total of six breast cancer cell lines (MCF7, MDA-MB-361, BT474, MDA-MB-453, MDA-MB-231 and BT20) were cultured in MEM (Sigma-Aldrich; Merck KGaA), and five (ZR75-1, T47D, ZR75-30, SKBR3 and AU565) were cultured in RPMI-1640 (Sigma-Aldrich; Merck KGaA) at 37°C (5% CO2) in a humidified atmosphere. DNA and mRNA were extracted from 10E+6 cells from each cell line using the DNeasy Blood & Tissue Kit and the RNAeasy Mini Kit (both Qiagen GmbH), respectively. The DNA was subjected to RE-dMSP, and the copy number of methylated RASSF1A per cell was obtained. Briefly, 1 µg total RNA was reverse-transcribed into cDNA using the ReverTra Ace® qPCR RT kit (Toyobo Life Science), and CK19 mRNA expression was assessed using the Light Cycler 480 Real-time PCR System (Roche Applied Science) with the following conditions: 95°C for 10 min, followed by 50 cycles at 95°C for 15 sec and 60°C for 60 sec, with a final cycle at 50°C for 10 sec. KRT19 (CK19) TaqMan® Gene Expression Assays (Hs01051611_gH; Applied Biosystems; Thermo Fisher Scientific, Inc.) were used to
87 Patients underwent surgery with SLB by OSNA assay

RASSF1A-methylation positive tumors (71 patients)

166 OSNA lysates from 161 SNs

SLN Metastasis positive (12 patients)

18 Metastatic SNs and 6 non-metastatic SNs

16 Patients excluded
- OSNA lysates not available (n=10)
- RASSF1A-methylation negative tumors (n=6)

Figure 1. Flowchart of the patient selection process for detecting methylated RASSF1A in SNs. RASSF1A, Ras association domain-containing protein 1; SN, sentinel node.

Figure 2. Schematic of the primers and probe used for RE-dMSP of the RASSF1A promoter. The location of the primers and probe, and the recognition sites of three methylation-sensitive restriction enzymes (HpaII, HhaI and BstUI) are presented. RE-dMSP, PCR with methylation-specific restriction enzymes; RASSF1A, Ras association domain-containing protein 1.

Conduct real-time PCR. The relative CK19 mRNA expression level per cell was obtained, and a PCR product was used as the standard.

Statistical analysis. Statistical analyses were performed using JMP Pro 11.2.0 (SAS Institute, Inc.) or GraphPad Prism 6 software (GraphPad Software, Inc.). The association between clinicopathological parameters and the copy number of methylated DNA or CK19 mRNA in SNs was evaluated using Fisher's exact test. Associations between the copy number of methylated DNA and CK19 mRNA in lysates were evaluated using the Wilcoxon signed-rank sum test. Differences in the copy number ranges of methylated DNA and CK19 mRNA among breast cancer cell lines were evaluated using the F-test.

Results

Sensitivity of RE-dMSP. The sensitivity of RE-dMSP was evaluated for the detection of methylated RASSF1A, using 0, 1, 3, 10, 30 and 100 copies of methylated DNA spiked in 10,000 copies of unmethylated DNA per well. A linear correlation was observed across all concentrations of methylated RASSF1A between the input copy number and the RE-dMSP results (Fig. 3A). No copies of methylated RASSF1A were detected in the 100% unmethylated DNA samples (data not shown), indicating that methylated RASSF1A was completely removed by restriction enzyme digestion. The assay results without restriction enzymes accurately represented the total amount of input DNA. The detection sensitivity of RE-dMSP in eight wells was 37.5, 62.5 and 100% for 1, 3 and ≥10 copies
of methylated DNA, respectively, while that of qMSP was 0, 25 and 100% for ≤10, 30 and 100 copies of methylated DNA, respectively. This indicated that RE-dMSP was ≥10 times more sensitive than conventional qMSP following bisulfite modification (Fig. 3B). Considering the probability distribution of methylated DNA in the templates (according to the binominal model), the sensitivity of RE-dMSP was estimated to be between two and three copies per well.

**RE-dMSP using SN lysates for OSNA.** Using the primary tumor samples of 77 breast cancer patients who underwent SNB and OSNA, RASSF1A methylation was screened by RE-dMSP; 71 (92.2%) of the samples were revealed to exhibit RASSF1A methylation (Fig. 1). The patient clinicopathological characteristics are presented in Table I. Of these 71 patients, 12 (16.9%) possessed SN metastases. In total, 161 SNs from these 71 patients were analyzed using OSNA, including 18 positive and 143 negative SNs. Among the 161 SNs, RASSF1A-methylation analysis was performed by RE-dMSP, and methylation was detected in 22 SNs from 14 patients. The amount of total DNA in the SN lysates ranged from 1,600 to 1,593,000 copies per 100 µl, confirming successful DNA extraction from all samples. Methylated RASSF1A was observed significantly more frequently in patients with large tumors that exhibited positive lymphovascular invasion (Table I). The expression levels of CK19 mRNA also exhibited a similar trend, although the difference was not significant. The relationship between the amounts of methylated RASSF1A and CK19 mRNA in SNs is presented in Fig. 4A. Methylated RASSF1A was detected in all of the SNs in which CK19 mRNA was highly expressed [OSNA (+) SNs (range, 9.8-95,000 copies/assay; n=13), and methylated RASSF1A was not present in SNs in which CK19 mRNA was not detected [OSNA (N.D.); n=91] (Fig. 4B). Methylated RASSF1A was detected in three of the five OSNA (+) SNs (60%; range, 7.4-12,800 copies/assay), and in six of the 52 OSNA (-) SNs (11.5%; range, 19.8-348 copies/assay). The concordance rate between the methylated RASSF1A status and the OSNA results was 95.0% (153/161). In the six RASSF1A-methylation (+) and OSNA (-) SNs from five patients (one patient possessed two SNs), immunohistochemistry was used to assess CK19 protein expression in the primary tumors; the results revealed strong-positive staining in all five patient samples (Fig. S1).

**Detection of SN metastasis by dPCR for the PIK3CA mutation.** To further investigate whether the methylated RASSF1A was derived from unexpected methylation in non-tumor cells of the SN (including lymphocytes), mutational analysis of DNA fragment size of methylated RASSF1 in SNs. It has previously been reported that circulating tumor DNA (ctDNA) generated in primary tumors can be detected in SNs (22). ctDNA is segmented into <180 bp fragments by apoptosis, and can therefore be detected by the short amplicon dPCR product (96 bp) of RE-dMSP (23,24). By contrast, metastatic tumor cells in SNs can produce long DNA fragments of methylated RASSF1A. In the present study, DNA fragment size was assessed to determine whether the methylated RASSF1A detected in SNs was derived from tumor cells, or from methylated RASSF1A fragments from the primary tumor migrating through the lymphatic vessels. A total of six methylated RASSF1A-positive, CK19 mRNA-negative SNs were selected. The SN lysates were available from three of these SNs and subjected to the following experimental procedures: Total DNA extracted from the lysates was separated into short (<500 bp) and long (>500 bp) DNA fractions by agarose gel electrophoresis, and evaluated by RE-dMSP (Fig. S2A). Methylated RASSF1A was detected in the long DNA fractions of all three SNs, and in the short fractions of two SNs (Fig. S2B). Given that all methylated RASSF1A-positive SNs contained long DNA fragments, SN-associated methylated RASSF1A was considered to originate from tumor cells in the SN, and not from the primary tumor.
Table I. Association between patient clinicopathological parameters and RASSF1A methylation or CK19 mRNA expression in SNs.

<table>
<thead>
<tr>
<th>Variables</th>
<th>n</th>
<th>Positive</th>
<th>Negative</th>
<th>P-value</th>
<th>Positive</th>
<th>Negative</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total patients</td>
<td>71</td>
<td>14</td>
<td>57</td>
<td>12</td>
<td>59</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;50</td>
<td>23</td>
<td>7</td>
<td>16</td>
<td>0.107</td>
<td>5</td>
<td>18</td>
<td>0.332</td>
</tr>
<tr>
<td>≥50</td>
<td>48</td>
<td>7</td>
<td>41</td>
<td></td>
<td>7</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Tumor size (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>40</td>
<td>4</td>
<td>36</td>
<td>0.033</td>
<td>3</td>
<td>37</td>
<td>0.025</td>
</tr>
<tr>
<td>≥20</td>
<td>31</td>
<td>10</td>
<td>21</td>
<td></td>
<td>9</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Histological grade</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1, 2</td>
<td>53</td>
<td>11</td>
<td>42</td>
<td>0.332</td>
<td>11</td>
<td>42</td>
<td>0.128</td>
</tr>
<tr>
<td>3</td>
<td>18</td>
<td>3</td>
<td>15</td>
<td></td>
<td>1</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>LVI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td>0.003</td>
<td>3</td>
<td>4</td>
<td>0.089</td>
</tr>
<tr>
<td>Negative</td>
<td>64</td>
<td>9</td>
<td>55</td>
<td></td>
<td>9</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>ER/PgR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>65</td>
<td>13</td>
<td>52</td>
<td>0.663</td>
<td>11</td>
<td>54</td>
<td>0.685</td>
</tr>
<tr>
<td>Negative</td>
<td>6</td>
<td>1</td>
<td>5</td>
<td></td>
<td>1</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>HER2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0.322</td>
<td>0</td>
<td>5</td>
<td>0.385</td>
</tr>
<tr>
<td>Negative</td>
<td>66</td>
<td>14</td>
<td>52</td>
<td></td>
<td>12</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Recurrence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>-</td>
<td>0</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Negative</td>
<td>71</td>
<td>14</td>
<td>57</td>
<td></td>
<td>12</td>
<td>59</td>
<td></td>
</tr>
</tbody>
</table>

RASSF1A, Ras association domain-containing protein 1; CK19, cytokeratin 19; LVI, lymphovascular invasion; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal receptor 2.

Figure 4. Association between the methylated RASSF1A copy number and CK19 mRNA expression in SN lysates of OSNA. (A) Correlation between the copy number (copies/assay) of methylated RASSF1A as determined by RE-dMSP, and CK19 mRNA expression as determined by OSNA. (B) The number of methylated RASSF1A-positive and -negative SNs is presented according to OSNA diagnoses; CK19 mRNA >5,000, (++); >250 and ≤5,000, (+); >0 and ≤250, (+); 0, (N.D.). RASSF1A, Ras association domain-containing protein 1; SN, sentinel node; CK19, cytokeratin 19; OSNA, one-step nucleic acid amplification; RE-dMSP, dPCR with methylation-specific restriction enzymes.
DNA, that corresponds to 150 tumor cells per node, showing a methylated RASSF1A by complete digestion of unmethylated methylation using dPCR following restriction enzyme digestion assay was developed to accurately measure RASSF1A alleles more precisely reflect the number of tumor cells. In order to detect SN tumor-derived DNA, an RE-dMSP analysis was conducted with 161 SN lysates, demonstrating a high concordance of 95% (153/161 SNs) with OSNA; eight discordant cases were found, including six OSNA (-)/methylation (+) and two OSNA (+)/methylation (-) SNs. The fact that the PIK3CA mutation status in the SN lysates revealed complete agreement with the RASSF1A methylation status indicates that non-tumorous cells in the lymph nodes do not exhibit RASSF1A methylation, because, if they did, a considerable amount of RASSF1A methylation would have been detected in PIK3CA mutation-negative SNs. Therefore, it is surmised that the six OSNA (-)/methylation (+) SNs are unlikely to have been RE-dPCR false-positives, and were more likely to be OSNA false-negatives. Since CK19 protein expression was confirmed in the primary tumors of all patients, most of these false-negatives are unlikely to be attributable to low CK19 mRNA expression within the tumor cells, although the possibility of low CK19 mRNA expression in CK19 protein-positive tumors still remains.

In addition, the DNA fragment size of methylated RASSF1A in the OSNA (-)/methylation (+) SN group was analyzed, in order to determine whether methylated RASSF1A originated from metastatic tumor cells in the SNs, or from primary tumors via the lymphatic vessels. Taking advantage of the fact that methylated RASSF1A from primary tumors has a small DNA fragment size (<500 bp; as it is generated from apoptosis), while that from metastatic tumor cells may be either short or long (>500 bp), the origin of the methylated RASSF1A was distinguished by analyzing DNA fragment size. In the present study, the presence of long DNA fragments was indicated in all three of the analyzed SNs, confirming the presence of tumor cells in SNs. Thus, it is highly likely that OSNA (-)/methylation (+) SNs reflect tumor metastases, and thus represent false-negatives from OSNA.

Only two of the SNs were OSNA (+)/methylation (-), suggesting the possibility of false-positives from RE-dMSP. However, in addition to being negative for RASSF1A methylation, these two SNs were also PIK3CA mutation-negative, although the corresponding primary tumors were positive for the PIK3CA mutation. Since RE-dMSP is sensitive enough to detect only a few copies per assay, it is unlikely that tumor cells in the SNs were missed by RE-dMSP; it is more likely that OSNA resulted in false-positives.

The TTL in SNs has been reported to correlate with the extent of non-SN metastases (28), and CK19 mRNA copies measured by OSNA have been used to estimate TTL in several predictive models (6,7). However, there is an ~30-fold difference in CK19 mRNA expression among breast tumors (9). In line with this, the present study also demonstrated a 10.8-fold difference in CK19 mRNA expression per cell in 10 breast cancer cell lines (plus one cell line that was CK19-negative). By contrast, the fold difference in the methylated RASSF1A copy number was as low as 2.8 among these 11 cell lines. This difference was assumed to result from a loss of heterozygosity (29) or aneuploidy (30-32). These results indicate that methylated RASSF1A can predict TTL more accurately than CK19 mRNA expression levels. At present, SN micrometastases

Discussion

In order to detect SN tumor-derived DNA, an RE-dMSP assay was developed to accurately measure RASSF1A methylation using dPCR following restriction enzyme digestion. RE-dMSP was able to detect as few as three copies of methylated RASSF1A by complete digestion of unmethylated DNA, that corresponds to 150 tumor cells per node, showing a sensitivity >10 times greater than that of the bisulfite method. A highly linear correlation between the RE-dMSP results and the amount of input DNA also ensured accurate and quantitative measurement of SN tumor cells.

The RE-dMSP assay, which was conducted with 161 SN lysates, demonstrated a high concordance of 95% (153/161 SNs) with OSNA; eight discordant cases were found, including six OSNA (-)/methylation (+) and two OSNA (+)/methylation (-) SNs. The fact that the PIK3CA mutation status in the SN lysates revealed complete agreement with the RASSF1A methylation status indicates that non-tumorous cells in the lymph nodes do not exhibit RASSF1A methylation, because, if they did, a considerable amount of RASSF1A methylation would have been detected in PIK3CA mutation-negative SNs. Therefore, it is surmised that the six OSNA (-)/methylation (+) SNs are unlikely to have been RE-dPCR false-positives, and were more likely to be OSNA false-negatives. Since CK19 protein expression was confirmed in the primary tumors of all patients, most of these false-negatives are unlikely to be attributable to low CK19 mRNA expression within the tumor cells, although the possibility of low CK19 mRNA expression in CK19 protein-positive tumors still remains.

In addition, the DNA fragment size of methylated RASSF1A in the OSNA (-)/methylation (+) SN group was analyzed, in order to determine whether methylated RASSF1A originated from metastatic tumor cells in the SNs, or from primary tumors via the lymphatic vessels. Taking advantage of the fact that methylated RASSF1A from primary tumors has a short DNA fragment size (<500 bp; as it is generated from apoptosis), while that from metastatic tumor cells may be either short or long (>500 bp), the origin of the methylated RASSF1A was distinguished by analyzing DNA fragment size. In the present study, the presence of long DNA fragments was indicated in all three of the analyzed SNs, confirming the presence of tumor cells in SNs. Thus, it is highly likely that OSNA (-)/methylation (+) SNs reflect tumor metastases, and thus represent false-negatives from OSNA.

Only two of the SNs were OSNA (+)/methylation (-), suggesting the possibility of false-positives from RE-dMSP. However, in addition to being negative for RASSF1A methylation, these two SNs were also PIK3CA mutation-negative, although the corresponding primary tumors were positive for the PIK3CA mutation. Since RE-dMSP is sensitive enough to detect only a few copies per assay, it is unlikely that tumor cells in the SNs were missed by RE-dMSP; it is more likely that OSNA resulted in false-positives.

The TTL in SNs has been reported to correlate with the extent of non-SN metastases (28), and CK19 mRNA copies measured by OSNA have been used to estimate TTL in several predictive models (6,7). However, there is an ~30-fold difference in CK19 mRNA expression among breast tumors (9). In line with this, the present study also demonstrated a 10.8-fold difference in CK19 mRNA expression per cell in 10 breast cancer cell lines (plus one cell line that was CK19-negative). By contrast, the fold difference in the methylated RASSF1A copy number was as low as 2.8 among these 11 cell lines. This difference was assumed to result from a loss of heterozygosity (29) or aneuploidy (30-32). These results indicate that methylated RASSF1A can predict TTL more accurately than CK19 mRNA expression levels. At present, SN micrometastases
(equivalent to ITCs) are considered to have little significance in prognosis (33). However, in these previous studies, SN metastases were usually evaluated by histological examination of a few representative sections of each SN, rather than a series of sections from each SN. On the other hand, RE-dMSP can detect metastases in each entire SN, thus quantification of TTL in each SN is considered to be more accurate than histological examination. Thus, it is possible that future RE-dMSP studies may disclose a new prognostic value for small SN metastases which are not detectable by histological examination.

A possible limitation of the present study is that RASSF1A methylation is not observed in all breast cancers, and its expression in the primary tumor is a prerequisite for RE-dMSP. In the present study, as many as 92.2% of breast tumors were RASSF1A methylation-positive; this was consistent with previous studies reporting frequencies of 90.4-97.8% (10,19), suggesting that RE-dMSP is applicable for use in >90% of breast tumors. Moreover, we had already reported that ≥1 of the three RASSF1A, GSTP1 and RARB2 genes is methylated in 98% of breast tumors, indicating that for RE-dMSP, the addition of GSTP1 and RARB2 to RASSF1A would enhance its applicability to nearly all breast tumors (10,34). OSNA has been repeatedly revealed to be as accurate as routine histological examination for the detection of SN metastases in unselected breast tumors (5), and is used in clinical practice in numerous countries. A lack of CK19 mRNA expression (a target of OSNA) has been reported in 1.6-3.0% of breast tumors (35,36). These results suggest that RE-dMSP targeting methylated GSTP1, RARB2 and RASSF1A genes may also be applicable to unselected breast tumors, much like OSNA. Further studies to pursue this possibility would be worthwhile.

The second limitation is that RE-dMSP cannot be used for the intraoperative diagnosis of SN metastasis, since it requires an overnight assay procedure. We believe that OSNA and RE-dMSP are complementary to each other for the detection of SN metastasis: OSNA is quicker than RE-dMSP and thus suitable for intraoperative analysis, while RE-dMSP provides a more accurate assessment of TTL, and is thus more suitable for postoperative analyses. The association between OSNA and RE-dMSP is analogous to that between intraoperative frozen and postoperative FFPE section analyses. Therefore, if the clinical significance of TTL determined by RE-dMSP is confirmed in the future, RE-dMSP may potentially be used alongside OSNA in daily practice, replacing the need for histological analysis. The third limitation was our limited sample size, which included only 161 LNs from 71 patients. We are currently working with other institutions to increase the sample population and hope to corroborate the findings in the future.

In conclusion, the present study demonstrated the development of an RE-dMSP assay to precisely detect RASSF1A methylation by methylation-specific restriction enzyme digestion, followed by dPCR. RE-dMSP was indicated to detect SN metastasis more accurately, and to estimate TTL more precisely than OSNA. However, the clinical utility of RE-dMSP requires further validation, including future studies with a greater number of patients.

Acknowledgements

Not applicable.

Funding

No specific grants were received from funding agencies in the public, commercial or not-for-profit sectors. SN received honoraria and research funding from Sysmex for research not related to the present study, and holds joint patents with Sysmex on subjects not related to the present study. YN also received honoraria from Sysmex, and holds joint patents with Sysmex on subjects not related to the present study.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

MA performed the experiments and analyzed the data. TM, TT, YN, MS, KS, and SJK collected the clinical samples. MA, NK and SN designed and drafted the manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The study was approved by the Ethical Review Board of Osaka University Hospital (approval date/number: 14 Aug 2014/#14111), and informed consent was obtained from each patient.

Patient consent for publication

Not applicable.

Competing interests

This study was supported in part by the research funding from Novartis, Pfizer, and Sysmex. Shinzaburo Noguchi has received research grant for other study from AstraZeneca and honoraria from AsstraZeneca, Novartis, Pfizer, and Sysmex, and has been an advisor for AstraZeneca and Novartis. Naofumi Kagara received honoraria from AstraZeneca and Novartis. Yasuto Naoi received honoraria from AstraZeneca and Sysmex and research grant from AstraZeneca for other study. Masafumi Shimoda received honoraria from Novartis. Kenzo Shimazu received honoraria from AstraZeneca. Seung Jin Kim received honoraria from AstraZeneca, Novartis and Pfizer. The other authors declare that they do not have a financial relationship with the organizations that sponsored the research.

References

Importance of assessing CK19 immunos


19. Aikawa F: A new molecular-based lymph node staging clas-
